Immunotherapy transforms cancer treatment.
作者信息
Zaidi Neeha, Jaffee Elizabeth M
出版信息
J Clin Invest. 2019 Jan 2;129(1):46-47. doi: 10.1172/JCI126046. Epub 2018 Dec 3.
Abstract
摘要
相似文献
1
Immunotherapy transforms cancer treatment.
J Clin Invest. 2019 Jan 2;129(1):46-47. doi: 10.1172/JCI126046. Epub 2018 Dec 3.
2
Immunotherapy: hype and hope.
Lancet Oncol. 2018 Jul;19(7):845. doi: 10.1016/S1470-2045(18)30317-6. Epub 2018 Jun 29.
3
Professor Jon Wigginton: where we are standing in immunotherapy.
Chin Clin Oncol. 2015 Mar;4(1):16. doi: 10.3978/j.issn.2304-3865.2014.01.01.
4
A new era for cancer immunotherapy based on the genes that encode cancer antigens.
Immunity. 1999 Mar;10(3):281-7. doi: 10.1016/s1074-7613(00)80028-x.
5
Overview: immunotherapy for cancer--is it time for the kitchen sink?
Curr Opin Investig Drugs. 2002 Jan;3(1):130-1.
6
Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment.
Nat Rev Clin Oncol. 2014 Nov;11(11):630-2. doi: 10.1038/nrclinonc.2014.174. Epub 2014 Oct 14.
7
"Immunotherapy of cancer: present status and future promise": Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd-25th September 2013.
Cancer Immunol Immunother. 2014 Sep;63(9):985-9. doi: 10.1007/s00262-014-1585-0. Epub 2014 Jul 24.
8
The case for cancer immunotherapy.
Drug Discov Today. 2003 Jun 15;8(12):530-1. doi: 10.1016/s1359-6446(03)02727-2.
9
Cancer immunotherapy in 2017: The breakthrough of the microbiota.
Nat Rev Immunol. 2018 Jan 30;18(2):87-88. doi: 10.1038/nri.2018.4.
10
[Unleashing NK cell signaling to improve cancer immunotherapy].
Med Sci (Paris). 2020 Oct;36 Hors série n° 1:50-55. doi: 10.1051/medsci/2020195. Epub 2020 Oct 14.
引用本文的文献
1
Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment.
Int J Mol Sci. 2025 Jul 16;26(14):6815. doi: 10.3390/ijms26146815.
2
Dual regulation of the cGAS-STING pathway: new targets and challenges for subtype-specific immunotherapy in breast cancer.
Front Oncol. 2025 Jun 10;15:1619097. doi: 10.3389/fonc.2025.1619097. eCollection 2025.
3
Endothelial Per-Arnt-Sim domain-containing protein 1 expression is correlated with poor prognosis and promotes invasion and metastasis in gastric cancer.
World J Gastrointest Oncol. 2025 Jun 15;17(6):105213. doi: 10.4251/wjgo.v17.i6.105213.
4
PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma.
Cancer Res Commun. 2025 Feb 1;5(2):339-348. doi: 10.1158/2767-9764.CRC-24-0515.
5
Pembrolizumab Leads to Complete Response in an HIV Patient With a Solid Tumor and a Cluster of Differentiation 4 (CD4) Count Less Than 100.
Cureus. 2024 Dec 13;16(12):e75680. doi: 10.7759/cureus.75680. eCollection 2024 Dec.
6
The pros and cons of probiotic use in pediatric oncology patients following treatment for acute lymphoblastic leukemia.
Front Pediatr. 2024 Oct 22;12:1427185. doi: 10.3389/fped.2024.1427185. eCollection 2024.
7
Quantifying collagen reorganization during immunotherapy in murine melanoma with second harmonic generation imaging.
Biophotonics Discov. 2024 May;1(1). doi: 10.1117/1.bios.1.1.015004. Epub 2024 May 20.
8
Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy.
Cancer Res Treat. 2025 Jan;57(1):1-10. doi: 10.4143/crt.2024.255. Epub 2024 Jun 5.
9
Reprogramming T-cell metabolism to enhance adoptive cell therapies.
Int Immunol. 2024 Apr 27;36(6):261-278. doi: 10.1093/intimm/dxae007.
10
A Review of 10-Year Survivability of Immunotherapy in the Management of Colon Cancer.
Cureus. 2023 Aug 9;15(8):e43189. doi: 10.7759/cureus.43189. eCollection 2023 Aug.
本文引用的文献
1
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
JCI Insight. 2018 Oct 18;3(20):122857. doi: 10.1172/jci.insight.122857.
2
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
3
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
4
Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
5
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7. doi: 10.1073/pnas.0830997100. Epub 2003 Apr 7.
6
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7. doi: 10.1073/pnas.192461099. Epub 2002 Sep 6.
7
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Nat Immunol. 2001 Mar;2(3):261-8. doi: 10.1038/85330.
8
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
J Exp Med. 2000 Oct 2;192(7):1027-34. doi: 10.1084/jem.192.7.1027.
9
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
Immunity. 1999 Aug;11(2):141-51. doi: 10.1016/s1074-7613(00)80089-8.
10
Enhancement of antitumor immunity by CTLA-4 blockade.
Science. 1996 Mar 22;271(5256):1734-6. doi: 10.1126/science.271.5256.1734.
Zotero 插件